Page last updated: 2024-08-24

dexfenfluramine and pergolide

dexfenfluramine has been researched along with pergolide in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Bhattacharyya, S; Davar, J; Mikhailidis, DP; Schapira, AH	1
Donis, N; Dulgheru, R; Fillet, M; Hego, A; Hulin, A; Lancellotti, P; Maréchal, P; Nchimi, A; Nguyen, ML; Oury, C; Tridetti, J	1

Reviews

1 review(s) available for dexfenfluramine and pergolide

Article	Year
Drug-induced fibrotic valvular heart disease. Lancet (London, England), 2009, Aug-15, Volume: 374, Issue:9689 Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents	2009

Article

Year

Drug-induced fibrotic valvular heart disease.

Lancet (London, England), 2009, Aug-15, Volume: 374, Issue:9689

Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents

2009

Other Studies

3 other study(ies) available for dexfenfluramine and pergolide

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling. International journal of molecular sciences, 2020, Jun-03, Volume: 21, Issue:11 Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Cell Proliferation; Cluster Analysis; Dexfenfluramine; Enzyme Activation; Extracellular Matrix; Female; Gene Expression Regulation; Heart Valve Diseases; Homeostasis; MicroRNAs; p38 Mitogen-Activated Protein Kinases; Pergolide; Rabbits; Sequence Analysis, RNA; Serotonin; Transcriptome; Transforming Growth Factor beta; Tricuspid Valve	2020